MARKET

SELB

SELB

Selecta
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.700
-0.020
-0.74%
Opening 14:19 07/09 EDT
OPEN
2.740
PREV CLOSE
2.720
HIGH
2.800
LOW
2.660
VOLUME
719.67K
TURNOVER
--
52 WEEK HIGH
4.830
52 WEEK LOW
1.280
MARKET CAP
236.22M
P/E (TTM)
-2.4211
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SELB stock price target is 8.43 with a high estimate of 13.00 and a low estimate of 4.000.

EPS

SELB News

More
Sarepta Addressing Gene Therapy Issue With Two Acquisitions
GuruFocus.com · 06/23 21:05
Selecta Biosciences Continues To Attract Partners As Sarepta Therapeutics Signs On For Gene Therapy
Seeking Alpha - Article · 06/23 19:12
Hedge Funds Aren’t Done Buying Selecta Biosciences, Inc. (SELB)
We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. I
Insider Monkey · 06/19 16:22
Selecta Biosciences (SELB) in Focus: Stock Moves 7.4% Higher
Selecta Biosciences (SELB) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Zacks · 06/19 12:49
Sarepta Therapeutics and Selecta Biosciences Enter Into Research License and Option Agreement for Selectas ImmTOR Immune Tolerance Platform in Neuromuscular Diseases
GlobeNewswire · 06/18 13:30
Sarepta Therapeutics and Selecta Biosciences Enter Into Research License And Option Agreement for Selecta's ImmTOR Immune Tolerance Platform In Neuromuscular Diseases
Benzinga · 06/18 12:40
It's Time To Invest In Selecta Biosciences As They Ink Massive $100 Million Upfront Deal
Seeking Alpha - Article · 06/18 11:30
Here's Why Selecta Biosciences Stock Is Soaring Today
MotleyFool.com · 06/18 04:00

Industry

Biotechnology & Medical Research
-0.25%
Pharmaceuticals & Medical Research
-0.66%

Hot Stocks

Symbol
Price
%Change

About SELB

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its product candidates are in various stages of clinical and preclinical development. Its SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company's lead product candidate, SEL-212, is a combination of a therapeutic enzyme and its SVP technology designed to be the biologic treatment for gout.
More

Webull offers kinds of Selecta Biosciences Inc stock information, including NASDAQ:SELB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SELB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SELB stock methods without spending real money on the virtual paper trading platform.